Exelixis is a globally ambitious oncology company innovating medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product. Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. Visit exelixis.com to learn more.